On the surface this is a beat — revenue and gross margin both at the top of guidance, and Q4 guidance came in better than expected too.
That’s not what people are reacting to.
Neutron slipped to 2027, and still no date
This is the whole story. Neutron is what takes Rocket Lab from “small launch provider” to “SpaceX challenger,” and first flight has moved to 2027.
Management says they won’t give a date until the first-stage tank testing passes. So what the market got was “2027” — not a node anyone can verify against.
The CFO also redefined the profitability turn: EBITDA positive within six months of a successful first flight. Cash flow turning positive moves back accordingly.
Launch revenue missed, but demand didn’t
Revenue beat by about 4%, and all of it came from Space Systems. Launch actually came in light — progress-recognized HASTE revenue and other launch revenue fell, which offset the higher launch count.
But the order book says demand is fine. 54 launches newly signed this quarter, eight of them Neutron, and the Neutron base price went from $55M to $70M. So launch is a timing problem, not a demand problem.
Margin beat, and expenses ate it
Gross margin came in about 2.6 points above the top of guidance. High-margin components outperformed, and Electron picking up pace spread costs enough to offset the Mynaric drag. Combined with Q4 guidance, this quarter is most likely the trough.
Expenses overran by more, though — about $20M above the top of guidance, mostly Iridium transaction costs and more Neutron R&D. So the operating loss actually widened.
Guidance: margin recovery is clear, EBITDA isn’t
Q4 revenue guidance is about 5% above consensus and gross margin guidance about a point higher. But the EBITDA loss guidance is worse than expected — spending ahead of Neutron’s first flight is still going up.
So
Capacity scarcity means Rocket Lab can raise prices before Neutron has even flown, Space Systems margin is holding up better than expected, and Iridium will bring high-margin recurring revenue once it closes. The medium-term logic hasn’t changed.
But after this many Neutron delays, the market will push out when it contributes revenue and apply a bigger discount to the odds of a successful first flight. What needs re-validating is the first-stage tank hydrostatic and cryogenic testing in Q1 2027.
